Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Petr Safranek is active.

Publication


Featured researches published by Petr Safranek.


Wiener Klinische Wochenschrift | 2007

Could we predict asymptomatic cardiovascular autonomic neuropathy in type 1 diabetic patients attending out-patients clinics?

Silvie Lacigova; Petr Safranek; Daniela Cechurova; Michal Krcma; Jakub Visek; Z. Jankovec; Michal Žourek; Iva Haladová; Zdeněk Rušavý

ZusammenfassungHINTERGRUND UND ZIELE: Die kardiovaskuläre autonome Neuropathie (KAN) ist bei Patienten mit Typ 1 Diabetes mellitus (DM1) mit einer erhöhten Morbidität und Mortalität verbunden. Diese Komplikation kann über lange Zeit ohne Symptome einhergehen. Ziel dieser Studie war es die Prävalenz, den Schweregrad und mögliche Vorhersageparameter der asymptomatischen KAN zu erfassen. PATIENTEN UND METHODEN: 107 Patienten mit DM1 (52 Männer, 55 Frauen, Alter 39,8 ± 12,4 Jahre [18–72]; Dauer des DM1: 16,6 ± 9,5 Jahre [0,5–43], Alter bei Manifestation 23,5 ± 12,8 Jahre [1–54], BMI 25,1 ± 3,2 [1,9–33,91]) wurden untersucht. Das Vorliegen einer KAN wurde mit Hilfe von Standard-Reflex-Testen (Ewing Batterie) erhoben und die Patienten wurden entsprechend den Ergebnissen in drei Gruppen eingeteilt: Gruppe 0 ohne KAN, Gruppe I mit erstgradiger KAN und Gruppe 2 mit zweitgradiger KAN. Wir erhoben außerdem die mit KAN am häufigsten einhergehenden chronischen Komplikationen des DM1, Episoden schwerer Hypoglykämie, zeitliche Parameter des DM1 (Patientenalter, Dauer des DM1, Alter bei Manifestation) und außerdem DM1-spezifische Parameter wie glykosyliertes Hb, BMI, kardiovaskuläre Erkrankungen und Blutdruck. Die Vorhersagbarkeit einer KAN wurde entsprechend den erhobenen Korrelationen beurteilt. ERGEBNISSE: Nur 50 der 107 der Patienten (46%) zeigten keine KAN. Bei 38 Patienten (36%) fanden wir eine erstgradige , bei 19 (18%) eine zweitgradige KAN. KAN korrelierte mehr mit der Dauer des DM1 (p < 0,001), als mit dem Alter der Patienten (p < 0,05). Es bestand eine grenzwertig signifikante Korrelation (p = 0,053) mit dem glykosylierten Hb. Weiters haben wir eine signifikant positive Korrelation zwischen KAN und dem Auftreten von chronischen Komplikationen (periphere Neuropathie: p < 0,001), Retinopathie: p < 0,001, Nephropathie: erhöhtes Kreatinin: p < 0,03, Albuminurie: p < 0,01) gefunden. Obwohl der Blutdruck bei allen Patienten im Normalbreich (124,2/74,5 ± 11,5/7,8 mmHg) lag, wurde eine positive Korrelation mit der KAN (p < 0,05) bestätigt. Zu den akuten Komplikationen des DM1 bestand keine Korrelation. SCHLUSSFOLGERUNGEN: Unsere Studie zeigt, dass die asymptomatische KAN bei Patienten mit DM1 sehr häufig ist. Mit Hilfe von multifaktorieller logistischer Regression konnten wir zeigen, dass bei gleichzeitigem Vorliegen von Albuminurie, peripherer Neuopathie und erhöhtem systolischem Blutdruck eine hohe Wahrscheinlichkeit für das zusätzliche Vorhandensein einer KAN besteht.SummaryBACKGROUND AND AIMS: Diabetic cardiovascular autonomic neuropathy (CAN) is associated with increased morbidity and mortality. This complication may be asymptomatic for a long time. The aim of this study was to assess the prevalence, severity and predictors of asymptomatic CAN in patients with type 1 diabetes mellitus (DM1). PATIENTS AND METHODS: 107 patients with DM1 were enrolled: 52 men and 55 women aged 39.8 ± 12.4 years (18–72), duration of DM 16.6 ± 9.5 years (0.5–43), age at DM manifestation 23.5 ± 12.8 years (1–54) and BMI 25.1 ± 3.2 (18.9–33.91). CAN was assessed using standard cardiovascular reflex tests (Ewing battery) and the patients were divided into three groups according to the results: Group 0, without CAN; Group I, 1st degree CAN; Group II, 2nd degree CAN. We assessed the most frequent relationships between CAN and chronic complications, episodes of severe hypoglycemia, time-related parameters (age of patients, duration of diabetes, age at manifestation), glycosylated hemoglobin (HbA1c), BMI, cardiovascular diseases and blood pressure, and determined the predictability of CAN on the basis of these relationships. RESULTS: Only 50 of the 107 patients (46%) showed no CAN. We found 1st degree CAN in 38 patients (36%) and 2nd degree CAN in 19 (18%). CAN correlated more significantly with the duration of diabetes (p < 0.001) than with age (p < 0.05). The relationship between CAN and HbA1c was on the borderline of statistical significance (p = 0.053). We found a positive correlation between CAN and the presence of chronic complications [peripheral neuropathy (p < 0.001), retinopathy (p < 0.001), and some markers of nephropathy: creatinine (p < 0.03), albuminuria (p < 0.01)]. Although blood pressure was within the physiological range (124.2/74.5 ± 11.5/7.8 mmHg) in all patients, a positive correlation with CAN was confirmed (p < 0.05). No relationship with occurrence of severe hypoglycemia was found. CONCLUSIONS: According to our results, asymptomatic CAN is very frequent in patients with DM1. By using multifactorial logistic regression (step-wise) analysis we demonstrated that if albuminuria, peripheral neuropathy and elevated systolic BP are present simultaneously, there is a high probability that the patient also has CAN (84.9% of initial group correctly predicted, p < 0.001).


International Journal of Chronic Obstructive Pulmonary Disease | 2014

Czech multicenter research database of severe COPD

Barbora Novotna; Vladimir Koblizek; Jaromir Zatloukal; Marek Plutinsky; Karel Hejduk; Zuzana Zbozinkova; Jiri Jarkovsky; Ondrej Sobotik; Tomas Dvorak; Petr Safranek

Purpose Chronic obstructive pulmonary disease (COPD) has been recognized as a heterogeneous, multiple organ system-affecting disorder. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) places emphasis on symptom and exacerbation management. The aim of this study is examine the course of COPD and its impact on morbidity and all-cause mortality of patients, with respect to individual phenotypes and GOLD categories. This study will also evaluate COPD real-life patient care in the Czech Republic. Patients and methods The Czech Multicentre Research Database of COPD is projected to last for 5 years, with the aim of enrolling 1,000 patients. This is a multicenter, observational, and prospective study of patients with severe COPD (post-bronchodilator forced expiratory volume in 1 second ≤60%). Every consecutive patient, who fulfils the inclusion criteria, is asked to participate in the study. Patient recruitment is done on the basis of signed informed consent. The study was approved by the Multicentre Ethical Committee in Brno, Czech Republic. Results The objective of this paper was to outline the methodology of this study. Conclusion The establishment of the database is a useful step in improving care for COPD subjects. Additionally, it will serve as a source of data elucidating the natural course of COPD, comorbidities, and overall impact on the patients. Moreover, it will provide information on the diverse course of the COPD syndrome in the Czech Republic.


Archive | 2017

Prospective Assessment of Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Categories and Chronic Obstructive Pulmonary Disease (COPD) Phenotypes: Evolution During Two Years

Vladimir Koblizek; Jan Švancara; Karel Hejduk; Michal Svoboda; Marek Plutinský; Jaromir Zatloukal; Kristián Brat; Eva Volakova; Patricie Popelkova; František Salajka; Lucie Heribanova; Petr Safranek; Ondrej Sobotik; Miroslava Fecaninova; Petr Vanik; Pavlina Musilova; Jaroslav Lnenicka; Tomas Dvorak; Vladimir Rihak; Kateřina Neumannová; Barbora Novotna; Eva Kocova; Michal Kopecky; M. Sipkova; Jiří Jarkovský


European Respiratory Journal | 2017

Respiratory parameters predict mortality in COPD patients - data from the Czech multicentre research database of severe COPD

Kristián Brat; Vladimir Koblizek; Marek Plutinsky; Jaromir Zatloukal; Patrice Popelkova; Tomas Dvorak; Petr Safranek; Ondrej Sobotik; Alena Vlachova; Petr Vanik; Zuzana Liptakova; Lucie Heribanova; Blanka Snelerova; Pavlina Musilova; Maria Majerciakova; Tomas Vencalek; Eva Kocova; Barbora Novotna; Michal Kopecky; Ondrej Kudela; Katerina Neumannova; Eva Volakova; Karel Hejduk; Jan Švancara; Jiri Jarkovsky; Michal Svoboda


European Respiratory Journal | 2017

Prospective assessment of GOLD 2017 categories and COPD phenotypesCzech Multicentre Research Database of COPD Group

Vladimír Koblížek; Marek Plutinsky; Jaromir Zaloukal; Patrice Popelkova; Tomas Dvorak; Petr Safranek; Ondrej Sobotik; Lucie Heribanova; Petr Vanik; Zuzana Liptakova; Blanka Snelerova; Jaroslav Lnenicka; Pavlina Musilova; Maria Majerciakova; Milada Sipkova; Barbora Novotna; Miroslava Fecaninova; Kristián Brat; Eva Volakova; Libor Nevoranek; Eva Kocova; Michal Kopecky; Katerina Neumannova; Karel Hejduk; Michal Svoboda; Jiri Jarkovsky


European Respiratory Journal | 2017

Assessment of nutrition and muscle mass loss in patients with severe COPD.

Eva Volakova; Jaromir Zatloukal; Marek Plutinsky; Patrice Popelkova; Tomas Dvorak; Petr Safranek; Ondrej Sobotik; Alena Vlachova; Petr Vanik; Zuzana Liptakova; Lucie Heribanova; Blanka Snelerova; Pavlina Musilova; Maria Majerciakova; Tomas Vencalek; Eva Kocova; Barbora Novotna; Michal Kopecky; Ondrej Kudela; Katerina Neumannova; Kristián Brat; Karel Hejduk; Jan Švancara; Jiri Jarkovsky; Michal Svoboda; Vladimir Koblizek


European Respiratory Journal | 2017

Therapy of COPD based on clinical phenotypes

Jaromir Zatloukal; Eva Volakova; Marek Plutinsky; Patricie Popelkova; Tomas Dvorak; Petr Safranek; Ondrej Sobotik; Alena Vlachova; Petr Vanik; Zuzana Liptakova; Lucie Heribanova; Blanka Snelerova; Pavlina Musilova; Maria Majerciakova; Tomas Vencalek; Eva Kocova; Barbora Novotna; Michal Kopecky; Ondrej Kudela; Katerina Neumannova; Kristián Brat; Karel Hejduk; Jan Švancara; Jiri Jarkovsky; Michal Svoboda; Vladimir Koblizek


European Respiratory Journal | 2016

Evolution of COPD phenotypes in time - Czech multicentre research database of severe COPD

Vladimir Koblizek; Barbora Novotna; Jan Švancara; Michal Svoboda; Patrice Popelkova; Marek Plutinský; Kristián Brat; Jaromir Zatloukal; Eva Volakova; Karel Hejduk; Eva Kocova; Michal Kopecky; Katerina Neumannova; Miroslava Fecaninova; Petr Safranek; Tomas Dvorak; Ondrej Sobotik; Zuzana Liptakova; Lucie Heribanova; Blanka Snelerova; Marie Majerciakova; Pavlina Musilova; Jiří Jarkovský


European Respiratory Journal | 2016

Risk scores for predicting death in COPD patients

Michal Svoboda; Jan Švancara; Jiří Jarkovský; Barbora Novotna; Patrice Popelkova; Marek Plutinský; Kristián Brat; Jaromir Zatloukal; Eva Volakova; Karel Hejduk; Eva Kocova; Michal Kopecky; Katerina Neumannova; Miroslava Fecaninova; Petr Safranek; Tomas Dvorak; Ondrej Sobotik; Zuzana Liptakova; Lucie Heribanova; Blanka Snelerova; Marie Majerciakova; Pavlina Musilova; Vladimir Koblizek


Studia pneumologica et phthiseologica | 2015

Distribuce klinických fenotypů v populaci nemocných s těžkou chronickou obstrukční plicní nemocí (pilotní analýza vstupních dat České multicentrické výzkumné databáze těžké CHOPN)

Vladimír Koblížek; Barbora Novotna; Eva Kocova; Patricie Popelkova; Marek Plutinský; Jaromir Zatloukal; T. Dvořák; Ondrej Sobotik; Petr Safranek; Blanka Snelerova; Lucie Heribanova; Pavlina Musilova; Marie Majerciakova; Tomas Vencalek; Karel Hejduk; Rudolf Praus; Magda Vytřísalová; Miloslav Hronek; Miroslav Kovařík Ph.D; Kateřina Neumannová; M. Kopecký; Zuzana Zbožínková; Jiří Jarkovský; Jan Švancara; Ladislava Pavlikova; Tomáš Konečný; Marek Orban; Petr Vanik; Zuzana Liptakova; M. Marel

Collaboration


Dive into the Petr Safranek's collaboration.

Top Co-Authors

Avatar

Barbora Novotna

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lucie Heribanova

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Eva Kocova

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ondrej Sobotik

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Michal Kopecky

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar

Vladimir Koblizek

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge